Table 3. Correlation of PPARγ expression with clinicopathological features of GC.
| Groups | n | PPARγ expression |
Positive rate (%) | χ2 | P | |||
|---|---|---|---|---|---|---|---|---|
| – | + | ++ | +++ | |||||
| Gender | 0.635 | 0.426 | ||||||
| Female | 54 | 22 | 30 | 2 | 0 | 59.26 | ||
| Male | 125 | 59 | 58 | 7 | 1 | 52.80 | ||
| Age (year) | 1.576 | 0.209 | ||||||
| ≤61 | 88 | 44 | 39 | 4 | 1 | 50.00 | ||
| >61 | 91 | 37 | 49 | 5 | 0 | 59.34 | ||
| Borrmann’s types | 7.321 | 0.007 | ||||||
| Bor I & II | 24 | 17 | 5 | 2 | 0 | 29.17 | ||
| Bor III & IV | 155 | 64 | 83 | 7 | 1 | 58.71 | ||
| WHO’s histological types | 0.001 | |||||||
| Papillary ade. | 2 | 2 | 0 | 0 | 0 | 0.00 | ||
| Well-diff. ade. | 13 | 1 | 11 | 1 | 0 | 92.31 | <0.001* | |
| Moderately-diff. ade. | 68 | 25 | 37 | 6 | 0 | 63.24 | ||
| Poorly-diff. ade. | 73 | 43 | 28 | 1 | 1 | 41.10 | ||
| Undiff. car. | 4 | 0 | 4 | 0 | 0 | 100.00 | ||
| Mucinous ade. | 15 | 8 | 6 | 1 | 0 | 46.67 | ||
| SRC | 4 | 2 | 2 | 0 | 0 | 50.00 | ||
| Lauren’s types | 8.310 | 0.016 | ||||||
| Intestinal | 83 | 28 | 48 | 7 | 0 | 66.27 | ||
| Diffuse | 81 | 45 | 34 | 1 | 1 | 44.44 | ||
| Mixed | 15 | 8 | 6 | 1 | 0 | 46.67 | ||
| Lymph node metastasis | 0.031 | 0.861 | ||||||
| No | 52 | 23 | 26 | 3 | 0 | 55.77 | ||
| Yes | 127 | 58 | 62 | 6 | 1 | 54.33 | ||
| Clinical stage | Fisher | 0.812* | ||||||
| I-II | 65 | 31 | 32 | 2 | 0 | 52.31 | ||
| III-IV | 114 | 50 | 56 | 7 | 1 | 56.14 | ||
ade., adenocarcinomas; diff., differentiated; car., carcinoma; *, expression of PPARγ decreases from well-, through moderately-, to poorly-diff. ade., rk=–0.299. PPARγ, peroxisome proliferator activated receptor-gamma; GC, gastric carcinoma; SRC, signet ring cell carcinomas.